Immunosuppression for kidney transplant recipients: Current strategies;Inmunosupresión para receptores de trasplante renal: Estrategias actuales

Revista de Investigacion Clinica

Volumn 57, Issue 2, 2005, Pages 213-224

  Alberú Gómez, Josefina ^a   Urrea, Eduardo Mancilla ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Immunosuppression; Renal transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER; CANCER RISK; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TOLERANCE; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM CARE; NEPHROTOXICITY; REVIEW; THROMBOCYTOPENIA;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CALCINEURIN; CYCLOSPORINE; GRAFT REJECTION; GROWTH INHIBITORS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PROTEIN KINASES; RECEPTORS, INTERLEUKIN-2; SIROLIMUS; TACROLIMUS;

EID: 25444511559     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Harrison JH, Merrill JP, Murray JE. Renal homotransplantations in identical twins. Surg Forum 1956; 6: 432-6.
2. Merion RM, White DJG, Thiru S, Evans DB, Calne RY. Cyclosporine: five-years experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148-54.
3. Cecka JM. The UNOS scientific renal transplant registry. In: Cecka JM, Terasaki PI (Eds.) Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory; 1996, p.1-14.
4. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32.
5. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadeveric renal transplantation. Transplantation 1997; 63: 977-83.
6. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988-96. N Engl J Meds 2000; 342: 605-12.
7. Sayegh M. Watschinger, B. Carpenter C. Mechanisms of T cell recognition on alloantigen: the role of peptides. Transplantation 1994; 57: 1295-302.
8. Sayegh M, Turka L. The role of T cell co-stimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-21.
9. Kahan B. Cyclosporin. N Engl J Med 1989; 321: 1725-38.
10. Bennet W, Dem Mattos A, Meyer M, Andoh T, Barry J. Chronic cyclosporine nephropathy: the Achilles heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-100.
11. Shin G, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-b 1 in humans: stimulation by cyclosporine. Transplantation 1998; 65:313-18.
12. Otto MG, Mayer AD, Clarien PA, et al. Randomized trial of cyclosporine micro-emulsion (Neoral) vs. conventional cyclosporine in liver transplantation: MILTON study. Multicenter International Study in Liver Transplantation of Neoral. Transplantation 1998; 66: 1623-40.
13. First MR, Alloway R, Schroeder TJ. Development of Sang-35: a cyclosperine formulation bioequivalent to Neoral. Clin Transplant 1988; 12: 518-24.
14. Kolars JC, Merion RM, Awni WM, Watkins PB. First-pass metabolism of cyclosporine by the gut. Lancet 1991; 338: 1488-90.
15. Mueller EA, Kovarik JM, Van, Bree JB, et al. Pharmacokinetics and tolerability of a micro-emulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178.
16. Kovarik JM, Mueller EA, Van Bree JR, et al. Within day consistency in cyclosporine pharmacokinetics from a micro-emulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232-7.
17. Kovarik JM, Mueller EA, Van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a micro-emulsion formulation: multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 1-5.
18. Mueller EA, Kovarik JM, Van Bree JB, et al. Improved dose-linearity of cyclosporine pharmacokinetics from a micro-emulsion formulation. Pharmacol Res 1994; 11: 301-4.
19. Min DI, Peery PJ, Chen HY, Hunsicker LG. Cyclosporine through concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy 1998; 18(2): 282-1.
20. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73(9 suppl): S19-22.
21. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomycin's, II. Immunosuppressive effect of FK-506 in vitro. J Antibiotics 1987; 40: 1256-65.
22. Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44: 729-33.
23. Kino T, Inamura N, Sakai F, et al. Effect of FK506 on human mixed lymphocyte reacti on in vitro. Transplant Proc 1987; 19: 36-9.
24. Todo S, Ueda Y, Demetris JA, et al. Immunosuppression of canine, monkeys and baboon allografts by FK506; with special reference to synergism with other drugs and to, tolerance induction. Surgery 1988; 104: 239-49.
25. Nickeleit V, Hirsch HH, Zeiler M y cols. BK-virus nephropathy in renal transplants: tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15(3): 324-32.
26. Agha I, Álvarez A, López-Rocafort L, et al. A prospective evaluation of BK virus infection in renal transplant recipients (abstr). Am J Transplant 2002; 2(suppl 3): 260
27. Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a caleineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4: 2132-4.
28. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000; 14(2): 65-81.
29. Behrens O, Kohlhaw K, Gunter H, et al. Detection of cyclosporine A in breast milk: is breast feeding contraindicated? Geburtshilfe fraunenheikunde 1989; 49: 207-9.
30. Kronbach T, Fisher V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the mayor cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5.
31. Knoll GA, Bell RC. tacrolimus vs. cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ 1999; 318(7191): 1104-7.
32. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine micro-emulsion in renal transplantation: a randomized multicenter study. Lancet 2002; 359(9308): 741-6.
33. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved graft survival at five-years. Transplantation 2002; 73(5): 775-82.
34. Kaplan B, Schold, JD, Meier-Kriesche HU. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980-4.
35. Mayer AD. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34(5): 1491-2.
36. Helderman JH, Bennett WM, Cibrik DM, et al. Immunosuppression: practice and trends. Am J Transplant 2003; 3(suppl. 4): 41-52.
37. Jin YJ, Burakoff SJ, Bierer BE. Molecular cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25. J Biol Chem 1992; 261: 10942-5.
38. Dumont FJ, Staruch MJ, Koprak SL, Melino MR Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144:251-8.
39. Heitman J, Movva NR, Hall MN. Target for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253: 905-9.
40. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660
41. Burke SE, Lubbers NL, Chen YW, et al. Meointimal formation after balloon-induced vascular injury in Yucatan mini-pigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 1999; 33(6): 829
42. Ikonen TS, Gummert IF, Hayase M, et al. sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969.
43. McTaggart RA, Gottlieb D, Brooks J, et al. sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3(4): 416-23.
44. Giessing M, Budde K. sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem? Nephrol Dial Transplant 2003; 18(2): 448-9.
45. Kahan, BD. Two-year results of multicenter phase III, randomized, controlled, safety and efficacy study of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003; 35(3 suppl): S37-51.
46. Groth CG, Backman L, Morales JM, et al. sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine: sirolimus European renal transplant study group. Transplantation 1999; 67(7): 1036-42.
47. Kreis H, Cisterne JM, Land W, et al. sirolimus in association with Mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69(7): 1252-60.
48. Johnson RW, Kreis H, Oberbauer R y cols. sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72(5): 777-86.
49. Oberbauer R, Kresi H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study. Transplantation 2003; 76(2): 364-70.
50. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74(11): 1560-7.
51. Mota A, Arias M, Taskinen, et al. sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3-years. Am J Transplant 2004; 4: 953-61.
52. Sievers T, Rossi S, Ghobrial R, et al. Mycophenolate mofetil. Pharmacotherapy 1997; 17: 1178-97.
53. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection: the international Mycophenolate mofetil renal transplant study groups. Transplantation 1997; 63(1): 39-47.
54. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Long-term use of Mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68-73.
55. Ojo AJ, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-9.
56. Azuma H, Binder J, Heeman U, et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460-6.
57. Squifflet JP, Backman L, Claesson K y cols. Dose optimization of Mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72(1): 63-9.
58. Weir MR, Fink JC, Hanes DS, et al. Chronic allograft nephropathy: Effect of cyclosporine reduction and addition of Mycophenolate mofetil on progression of renal disease. Transplant Proc 1999; 31: 1286-7.
59. Weir MR, Traver Ward M, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-73.
60. Granger DK. Enteric-coated Mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001; 33(7-8): 3241-4.
61. Vincenti F, Pace D, Birnbaum J Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3(1): 50-2.
62. Ekberg H, Backman L, Tufveson G, et al. daclizumab prevents acute rejection and improves patient survival post transplantation: 1-year pooled analysis. Transpl Int 2000; 13(2): 151-9.
63. Morales-Buenrostro LE, Ortiz-Arroyo VM, Pérez-Garrido J, Correa-Rotter R, Alberú-Gómez J. Reducción en la frecuencia de rechazo agudo en receptores de trasplante renal de donador vivo con el uso de dosis reducida de daclizumab (2mg/kg). Revista de Resúmenes de la LIII Reunión Anual del Instituto Mexicano de Investigaciones Nefrológicas: 160.
64. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72(5): 839-45.
65. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab vs. placebo for control of acute cellular rejection in renal allograft recipients: CHIB 201 international study group. Lancet 1997; 350(9086): 1193-8.
66. Lawsen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimerical anti-interleukin-2 receptor monoclonal antibody, in combination with Mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75(1): 37-43.
67. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin vs. Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67(7): 1011-8.
68. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66(1): 29-37.
69. Hardinger KL, Schnitzler M, Miller B y cols. Long-term comparison of Thymoglobulin versus Atgam for induction in adult renal transplantation: evidence of improved allograft survival at 5-years [abstr]. Am J Transplant 2003; 3: 556.
70. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337-42.
71. Norman DJ, Kahana I, Stuart FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55:44-50.
72. Knudsen PJ, Dinarello CA, Strom TB: Glucocorticoids inhibit transcription and post-transcriptional expression of interleukin-I. J Immunol 1987; 139: 4129-34.
73. Zanker B, Waltz G, Wieder KJ, Strom TB. Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49: 183-5.
74. Arya SK, Wong-Staal F, Gallo RC. Dexamethasone mediated inhibition of T cell growth factor and gamma interferon messenger RNA. J Immunol 1984; 133: 273-6.
75. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticosteroid-mediated inhibition of T-cell proliferation by the synergistic action of IL-1, IL-6, and IFN. J Immunol 1991; 146: 3523-7.
76. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian multicentre transplant study group. Can Med Assoc J 1992; 147(5): 645-57.
77. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000; 70: Suppl: SS41-SS45.
78. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-13.
79. Kahan BD. Individuality: the barrier to optimal Immunosuppression. Nature Rev Immunol 2003; 3: 831-8.
80. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-29.
81. Matthews JF, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003; 3: 794-803.